The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|October 27, 2017
EU Trials Register Now Holds Data on Over 50k Studies
Author(s)Philip Ward
Advertisement
Information about more than 50,000 clinical trials is now available on the European Union (EU) Clinical Trials Register.
The register contains data on 31,456 current trials with a EudraCT protocol, of which 5,048 are clinical trials conducted on subjects of less than 18 years of age. It also presents details about 18,700 older pediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
The register, which covers studies that started after May 1, 2004 allows users to search for protocol and results information on both interventional clinical trials that are conducted in the EU and the European Economic Area (EEA), as well as clinical trials conducted outside the EU/EEA that are linked to European pediatric medicine development.
It also maintains a list of patient/consumer organizations who may be able provide information on clinical trials within various disease areas. These are organizations that regularly work with the European Medicines Agency.
For more information about the initiative,
Philip Ward is the European Editor for Applied Clinical Trials.
Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Where AI Governance in Clinical Development Falls Short
3
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5